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Abstract
Background: In mdx mice, the absence of dystrophin leads to the deficiency of other components of the dystrophin-
glycoprotein complex (DAPC), making skeletal muscle fibers more susceptible to necrosis. The mechanisms involved in the
disappearance of the DAPC are not completely understood. The muscles of mdx mice express normal amounts of mRNA for
the DAPC components, thus suggesting post-transcriptional regulation.
Methodology/Principal Findings: We investigated the hypothesis that DAPC reduction could be associated with the
microRNA system. Among the possible microRNAs (miRs) found to be upregulated in the skeletal muscle tissue of mdx
compared to wt mice, we demonstrated that miR-222 specifically binds to the 39-UTR of b1-syntrophin and participates in
the downregulation of b1-syntrophin. In addition, we documented an altered regulation of the 39-UTR of b1-syntrophin in
muscle tissue from dystrophic mice.
Conclusion/Significance: These results show the importance of the microRNA system in the regulation of DAPC
components in dystrophic muscle, and suggest a potential role of miRs in the pathophysiology of dystrophy.
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Introduction
Dystrophin is a cytoplasmic protein belonging to a large
oligomeric complex (dystrophin-associated protein complex, or
DAPC) that associates with other proteins, including sarcoglycans,
syntrophins, dystroglycans, syntrobrevin, and sarcospan [1–3].
The DAPC plays an important structural role in linking the actin
cytoskeleton to the extracellular matrix. A disruption of the DAPC
impairs muscle fiber function; therefore, several myopathies are
due to genetic defects found in the DAPC proteins [3–11]. The
most common myopathies caused by a defect in the DAPC
complex are Duchenne Muscular Dystrophy (DMD) and its
milder form, Becker Muscular Dystrophy, which are both caused
by mutations in the X2linked dystrophin gene [4–6]. Defects
in sarcoglycan (SG) subunits are associated with an autosomal
recessive form of Limb Girdle Muscular Dystrophy [7,8].
Although no human diseases have been found to result from
mutations in the dystroglycan gene, impaired glycosylation of the
a-dystroglycan subunit due to defects in glycosyltransferases leads
to muscular disorders [9,10]. A deficiency of the syntrophin-
dystrobrevin subcomplex has been observed in patients with
inherited myopathy [11].
Different animal models are available to study the different
dystrophies. The most commonly used laboratory animal model of
DMD is the mdx mouse. In these animals, all the muscles lack
dystrophin, however, mdx mice show a much milder phenotype
than DMD patients [12]. Although the muscles of mdx mice are
affected to a different extent, physical exercise worsens the
pathology, similar to that observed in the human disease [13].
Genetically modified animal models that are deficient in the four
different SG subunits have also been developed, and their
phenotype is associated with skeletal and cardiac myopathies
[14–18].
Studies using these animal models of different myopathies
revealed that the DAPC is tightly regulated. A deletion or
mutation in the gene of one of the components of the DAPC leads
to destabilization of the entire complex and a strong reduction in
the intracellular concentration of the other proteins [14–19]. The
mechanisms involved in this phenomenon are not yet completely
understood. Because treatment with proteasome inhibitors, have
been shown to promote upregulation of the expression levels of
some members of the DAPC in mdx mice and in the muscular
explants obtained from patients with DMD or BMD, it has been
suggested that the degradation system is involved in inhibiting
DAPC proteins expression in dystrophy [20–22].
In recent years, mounting evidence has shown the pivotal role of
small, non-coding RNAs, such as microRNAs (miRs), in the
negative regulation of gene expression [23–25]. In the nucleus,
miRs are transcribed as long primary transcripts (pri-miRs) and
processed into 60–120 nucleotide hairpin precursors (pre-miRs),
which are exported to the cytoplasm where they are further
processed into mature 21–23 nucleotide transcripts. One of the
two strands of the mature microRNAs is incorporated into the
large protein complex, RISC (RNA-Induced Silencing Complex),
and guides the complex to the target mRNA. MicroRNA
modulation of gene expression can occur by blocking translation
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Several miRs (miR-1, miR-133, and miR-206) have been shown to
be specifically expressed in the skeletal muscle [26–32]. These
miRs could play a role in numerous muscular diseases, as
microarray analysis of muscle samples obtained from patients
affected by different muscular disorders, including DMD and
BMD, revealed that approximately 200 miRs were differentially
expressed [30,31]. Among these miRs, five (miR-146b, miR-221,
miR-155, miR-214, and miR-222) were found to be consistently
dysregulated in the different analyzed diseases [31]. In a recent
study, Greco et al. [32] reported the detection of a common
miRNA signature in muscles from mdx mice and DMD patients.
Here, 11 miRs were found to be dysregulated in both types of
samples and were suggested to be involved in the pathways
implicated in the response to muscle damage.
To date, no information is available regarding the function of
these dysregulated miRs in the different myopathies. We addressed
the potential role of miRs in the pathogenesis of DMD, consi-
dering that, in muscle tissue obtained from mdx and transgenic
mice (a-and b-sarcoglycan knockout mice) normal levels of mRNA
for the different components of the DAPC were detected, in spite
of the absence of the corresponding proteins, thus ruling out
transcriptional regulation of the specific mRNAs [14–19]. We
verified the possible involvement of the microRNA system as a
regulator of the DAPC proteins using the mdx mouse model of
DMD. We analyzed both mRNA and protein levels of syntrophins
and dystroglycans, and focused our study on evaluating the
regulation of b1-syntrophin. By analyzing the 39 untranslated
region (39UTR) of b1-syntrophin, we found that three miRs could
target this protein, and we established that one of these, miR-222,
is upregulated in the muscles of mdx mice and is involved in the
downregulation of the b1-syntrophin isoform in dystrophic
muscles.
Results
RNA and protein expression levels
It has been previously reported that when one of the DAPC
components is genetically absent, other proteins of the complex
are likewise reduced, and complex formation is ultimately
impaired. To confirm this phenomenon, we monitored the mRNA
levels, protein expression and immunolocalization of four DAPC
components (a- and b-dystroglycan and a, and b1-syntrophin) in
different muscles (gastrocnemius, tibialis, extensor digitorum
longus, diaphragm) obtained from normal and mdx dystrophic
mice.
The dystroglycan gene (Dag) encodes for a single polypeptide
that is post-translationally cleaved into two subunits, a-dystrogly-
can (a-dag) and b-dystroglycan (b-dag) [33]. Using quantitative
real time RT-PCR (qRT-PCR), a slight, but not significant
decrease in dag mRNA level, was observed in the gastrocnemius
muscles of young mdx mice compared to those of wild type (wt)
animals. With increasing age, a 50% decrease in dag mRNA level
was observed in the dystrophic muscles compared to the muscles
of wt adult animals (Fig. 1). Although the protein level of the a-dag
subunit was not statistically different between muscle tissues from
wt and mdx animals of the same age, a-dag was not correctly
localized at the sarcolemma of dystrophic muscle cells (Fig. S1A).
The protein level of b-dag tended to decrease in both young and
adult muscle tissues from dystrophic mice (Fig. S1B); similar to
that of the a-subunit, localization of the b-dag protein at the
sarcolemma was clearly impaired in the muscle tissues from
dystrophic mice (Fig. S1C). Taken together, these data suggest that
a small decrease in a- and b-dystroglycan protein levels occurs in
the gastrocnemius muscles of mdx dystrophic animals, probably
due to a reduction in Dag gene transcription.
Among the different syntrophin isoforms expressed in skeletal
muscle tissues, the a and b1 subunits are preferentially associated
with dystrophin and are encoded by two different genes [34]. The
mRNA level of the a isoform of syntrophin (a-synt) was slightly
increased in the gastrocnemius muscles of mdx mice (Fig. 2A).
There was no difference in a-syntrophin protein levels between the
normal and mdx animals; however, the protein was no longer
localized at the plasma membrane of dystrophic muscle fibers,
shown by immunofluorescence analysis (Figs. 2B and 2C). These
observations suggest that the absence of a-syntrophin at the cell
membrane is probably related to the absence of the entire DAPC
but not due to a reduction in its protein levels.
The mRNA level of b1-syntrophin in the muscles of adult mdx
mice was almost two-fold higher than that in the gastrocnemius
muscles of wt animals (Fig. 3A). Shown by western blot analysis, a
significant reduction in its protein level (approximately 40%), was
observed in the muscles of the adult dystrophic mice (Fig. 3B).
Similarly, a reduction of b1-syntrophin protein level was observed
when the protein was immunoprecipitated from the whole tissue
homogenates of mdx muscles compared to those of wt muscles
(Fig. S2). As expected, immunofluorescence analysis showed the
absence of b1-syntrophin in the plasma membrane of dystrophic
skeletal muscle fibers (Fig. 3C).
The same results were obtained when other types of muscles,
such as diaphragm, and extensor digitorum longus were
investigated (data not shown), suggesting that a reduction in b1-
syntrophin protein level is a general phenomenon.
These data showed that the levels of dystroglycans and a-
syntrophin were not significantly modified in dystrophic muscles.
In contrast, the level of b1-syntrophin was clearly decreased, and
this reduction in mdx muscles could not be explained by a decrease
in gene transcription. Therefore, our studies focused on post-
Figure 1. Dystroglycan mRNA expression. The mRNA levels from
the gastrocnemius muscle tissues of wt and mdx mice of different ages
(30 d, 30-day-old mice; 5 m: five-month-old mice) were assessed by
qRT-PCR; relative gene expression was calculated by the comparative Ct
method (2
2ddCt). The Ct values of each gene were normalized to the Ct
value of GAPDH in the same RNA sample. The mRNA levels in the mdx
samples are expressed as fold change compared to those in wt samples.
All values represent the mean 6 SD from experiments performed on
three different RNA preparations of the muscle tissues from wt and mdx
mice (see Methods). *P,0,05 versus wt (P=0,0465 measured by the
Mann-Whitney test).
doi:10.1371/journal.pone.0012098.g001
miR-222 in mdx
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syntrophin.
39-UTR analysis
The 39-untranslated regulatory regions (39-UTRs) of mRNAs
play an important role in the regulation of mRNA translation.
Therefore, we investigated whether the expression of b1-
syntrophin was differentially regulated in skeletal muscles between
mdx mice and wt mice, and whether this phenomenon was
dependent on the 39-UTR of b1-syntrophin. To this end, the 39-
UTR of the mRNA encoding b1-syntrophin was cloned into the
pEGPF-C1 expression vector, allowing us to assess 39-UTR
regulation by examining GFP expression. First, we verified that
the construct pEGFP-39-UTR-b1-synt was expressed in transiently
transfected COS1 cells, and that introduction of the 39-UTR of
b1-syntrophin into the plasmid did not constitutively induce GFP
expression (data not shown).
To test the hypothesis that the 39-UTR of b1-syntrophin is
differentially regulated in the muscles of dystrophic animals, the
pEGFP-39-UTR-b1-synt construct was electroporated into the
tibialis anterior muscle of wt and mdx mice. The electroporation
procedure induced minimal tissue damage, evaluated by histolog-
ical observation of the electroporated muscles (data not shown).
The results revealed that GFP was consistently detectable in
muscle fibers when the empty vector pEGPF-C1, or the pEGFP-
39-UTR-b1-synt construct were transfected into the muscles of wt
mice (Fig. 4A), indicating that the 39-UTR of b1-syntrophin does
not interfere with GFP expression in skeletal muscles of wt
animals. GFP expression was clearly detected in the muscle of mdx
mice electroporated with pEGPF-C1; however, the expression was
Figure 2. a-syntrophin mRNA and protein expression. A: The mRNA levels in the gastrocnemius muscle tissues from wt and mdx mice of
different ages (30 d, 30-day-old mice; 5 m: five-month-old mice) were determined by qRT-PCR and calculated by the comparative Ct method (2
2ddCt).
The Ct values of each gene are normalized to the Ct value of GAPDH in the same RNA sample. The mRNA levels in the mdx samples are expressed as
fold changes compared to those in wt samples. All values represent the mean 6 SD from three different experiments performed on different RNA
preparations of the muscle tissues from wt and mdx mice (see Methods). B: Total protein extracts from the gastrocnemius muscle tissues of wt and
mdx mice of the indicated ages were resolved by SDS-PAGE and probed with an a-syntrophin antibody. A representative western blot is shown. The
graph values represent the mean 6 SD of the densitometric analyses from three different experiments with different animal samples (see Methods).
Data are presented as the percentage of protein in mdx mice compared to that in wt mice, normalized to endogenous actin expression level. C:
Frozen sections of the gastrocnemius muscles obtained from wt and mdx adult mice were probed with an anti-a-syntrophin antibody and visualized
using a secondary antibody coupled to a fluorescent marker, FITC. A representative of the two performed analyses on two different five-months-old
wt and mdx mice, is shown.
doi:10.1371/journal.pone.0012098.g002
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pEGFP-39UTR-b1-synt (Fig. 4B).
These data demonstrated that, in the presence of the b1-
syntrophin 3-9UTR, GFP expression was impaired in the muscles
of mdx mice, suggesting a differential in vivo regulation of 39-UTR-
b1-synt between dystrophic muscles and wt muscles.
MicroRNA expression
MicroRNAs are well known regulators of protein expression
and their action is mediated by binding to the 3’-UTR of target
mRNAs. Since we have just shown that the b1-syntrophin 3’-UTR
is negatively regulated in dystrophic muscles, we considered the
potential role of microRNAs in the modulation of b1-syntrophin
expression. No data are currently available about which specific
miRs modulate the expression of DAPC proteins; for this reason,
to identify putative miR binding sites on the b1-syntrophin 39-
UTR, we took advantage of many computational programs
available to predict miRNA targets. We used the target prediction
programs, the Miranda package and targetscan, which use
microRNAs complementarity to predict target mRNAs. Among
the several miRs predicted to bind the b1-syntrophin 39-UTR,
three miRs (miR-222, miR-24, and miR-339) were identified by
the different databases utilized.
As the first step, we determined whether the three selected miRs
were expressed in myogenic cells, such as primary mouse satellite
cells and C2C12 cell lines, and in skeletal and heart muscle tissues
obtained from five-month-old wt mice. Northern blot analysis
revealed that all the three miRs were expressed in pooled samples
of skeletal muscle tissues, as well as in proliferating C2C12
myoblasts and differentiated myotubes (data not shown). Next, we
investigated whether the differential expression of these miRs
Figure 3. b1-syntrophin mRNA and protein expression. A: The mRNA levels in from the gastrocnemius muscle tissues of wt and mdx mice of
different ages (30 d, 30-day-old mice; 5 m: five-month-old mice) were determined by qRT-PCR and calculated by the comparative Ct method (2
2ddCt).
The Ct values from each gene are normalized to the Ct value of GAPDH in the same RNA sample. The mRNA levels in the mdx samples are expressed
as fold change compared to those in the wt samples. All values represent the mean 6 SD of four experiments performed on different RNA
preparations of the muscle tissues from wt and mdx mice (see Method). Statistical significance was determined as *P,0,05 (P=0,012 as measured by
the Mann-Whitney test). B: Total protein extracts from the gastrocnemius muscles of wt and mdx mice were resolved by SDS-PAGE and probed with
b1-syntrophin antibodies. A representative western blot is shown. The graph values represent the mean 6 SD of the densitometric analyses from four
independent experiments with different animal samples (see Methods). Data are presented as the percentage of protein in mdx mice compared to
that in wt mice, normalized to endogenous actin expression level. *P,0,05 versus wt (P=0,002 as measured by the Mann-Whitney test). C: Sections of
the gastrocnemius muscles of wt and mdx adult mice were probed with an anti-b1-syntrophin antibody and visualized using a secondary antibody
coupled to a fluorescent marker, FITC. A representative of the two performed analyses on different animals is shown.
doi:10.1371/journal.pone.0012098.g003
miR-222 in mdx
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animals. RNA was prepared from wt and mdx skeletal muscle
tissues at different ages (20-day, 30-day and five-month-old mice)
to follow the disease progression.
Northern blot analysis showed no significant differences in the
expression of miR-24 and miR-339 between normal and
dystrophic mRNA samples (data not shown). MiR-222 expression
was significantly elevated in the gastrocnemius muscles from mdx
mice compared to those from wt mice. In particular, a 50%
increase in miR-222 levels was observed in the muscles of 20- and
30-day-old mdx mice, and a maximum of three-fold increase was
evident in the muscles of five-month-old mdx animals (Fig. 5).
Thus, these results demonstrate that miR-222 is expressed in
skeletal muscles, and notably upregulated in mdx mice, suggesting a
potential role of miR-222 in downregulating b1-syntrophin
expression in dystrophic muscles.
Analysis of miR-222 responsive elements within the
39-UTR of b1-syntrophin
Todeterminewhetherthe b1-syntrophinmRNAistherealtarget
of miR-222, the activity of a luciferase reporter construct containing
the 39-UTR ofb1-syntrophinRNAwas evaluatedinthe presenceof
miR-222. To perform this experiment, the 39-UTR of b1-
syntrophin was cloned into the pGL3 vector, and the construct
was transiently transfected into COS1 cells cultured in the absence
orpresenceofdifferentconcentrationsofmiR-222.Attheendofthe
incubation time, the cells were lysed and processed to measure the
luciferase activity of the synthesized enzyme. The results showed
that luciferase activity was dose-dependently decreased by miR-222
andnoluciferase activitywasdetected whena‘‘scrambled’’negative
control or an anti-miR specific to miR-222 was used in its
place (Fig. 6A). The highest concentration of miR-222 employed
(5610
28M) caused a decrease of 50% in luciferase activity, in
agreement with the inhibitory effect observed in other cellular
systems by the same miR [35,36]. This result strongly suggested an
interaction between miR-222 and the 39-UTR of b1-syntrophin.
The 39-UTR of b1-syntrophin contains two putative consensus
sites for miR-222 binding. To confirm the target specificity of
miR-222, two pGL3-39UTR b1-syntrophin constructs, carrying
deletions of the complementary sequences that could potentially
be involved in the binding of miR-222, were used. Luciferase
activity was measured in the cells transfected with the vector
mutated in binding site 1 (mut1), or in binding site 2 (mut2), in the
presence of 5610
28M of miR-222. As shown in Fig. 6B, a
mutation of binding site 1 almost completely abolished the activity
of miR-222, whereas a mutation of binding site 2 only slightly
reduced miR-222 activity, indicating that the majority of miR-222
activity is due to the binding to the first consensus sequence.
Functional analysis
As shown by the luciferase activity assays, miR-222 efficiently
targeted the 39-UTR of b1-syntrophin. To address the role of
Figure 4. Gene delivery into tibialis muscles of wt and mdx mice. A: Micrographs of GFP expression in the muscle sections from tibialis
muscles of wt or mdx mice injected with 20 mg of DNA containing either pEGPF-C1 or pEGFP-39-UTR-b1-synt, and subjected to electric pulses. A
representative experiment is shown. B: The graph values represent the mean 6 SE of the percentage of GFP positive cells/muscle sections analyzed in
30-day old wt and mdx mice. Fifteen sections per experimental group (n=3 wt, n=4 mdx) were counted. *P,0,05 as measured by the unpaired t-
test.
doi:10.1371/journal.pone.0012098.g004
miR-222 in mdx
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the effect of overexpressing or silencing miR-222 on endogenous
b1-syntrophin levels in cells. b1-syntrophin is expressed at different
levels in several tissues, with the highest expression level observed
in the liver [37]. Therefore, to obtain a significant signal, the
hepatic cell line, Hep2, was used to assess b1-syntrophin
modulation in the presence of exogenous miR-222. The Hep2
cells were transfected with miR-222 and/or anti-miR-222, and b1-
syntrophin protein levels were determined by western blot. The
results showed that b1-syntrophin expression was reduced by
approximately 60% in the hepatic cells transfected with miR-222,
and its expression was restored in the cells co-transfected with
miR-222 and anti-miR-222 (Fig. 7A). This result indicates that
exogenous miR-222 reduces the protein level of endogenous b1
syntrophin, regardless of the cell origin.
The same experiment was performed in satellite myogenic cells
from the muscles of wt and mdx mice. When miR-222 was
overexpressed in satellite cells from wt mice, a 40% reduction in
b1-syntrophin level was observed; this reduction was abolished
when miR-222 activity was blocked by the corresponding
antagomir (Fig. 7B). In the satellite cells from dystrophic muscles
of young mice, the expression level of miR-222, measured by
qRT-PCR, was 50% higher than that in wt cells (data not shown).
No reduction in b1-syntrophin level in response to exogenous
miR-222 was observed in these cells, whereas treatment with anti-
miR-222 led to a slight increase in b1 syntrophin level, thus
counteracting the elevated endogenous level of miR-222 in the mdx
muscles (Fig. 7C). Taken together, these data demonstrate that
miR-222 regulates b1-syntrophin protein expression, and silencing
miR-222 can restore b1-syntrophin protein expression to normal
in dystrophic cells in culture.
Another potential role of miR-222 could be the modulation of
other miRs specifically expressed in skeletal muscles. Thus, we
investigated whether miR-222 is involved in the expression of
three myogenic miRs: miR-1, miR-133 and miR-206. To this end,
C2C12 cells were transfected with miR-222 or anti-miR-222. RNA
was then extracted and the expression levels of these myogenic
miRs were measured by qRT-PCR. The obtained results (Fig. S3)
showed that miR-222 regulated the expression of these myogenic
miRs: miR-222 overexpression reduced the expression of all these
three miRs. Conversely, anti-miR-222 treatment that inhibited
endogenous miR-222 exerted no effect on the expression of miR-
1, miR-133 and miR-206, probably due to the low miR-222
expression of in C2C12 cells.
Discussion
In this study, we investigated the possible mechanisms
regulating the expression of the dystrophin-associated protein
complex during the progression of muscular dystrophy. Dystro-
phin deficiency causes a disruption of the DAPC, with a drastic
reduction or loss of its components, and the absence of these
proteins in the plasma membrane of muscle cells [14–19]. The
presence of detectable levels of mRNA for the different protein
components of the DAPC, and the absence of the corresponding
proteins in the muscles of dystrophic mice, suggest the possible
involvement of a post-transcriptional mechanism of regulation.
While previous papers [20–22] documented the participation of
the proteasome degradation system, our study shows that other
mechanisms are involved in the regulation of DAPC, particularly,
the microRNA system plays an important role by modulating the
translation of the mRNA of some DAPC components.
MiRs are involved in several physiological systems including,
skeletal muscles [26–32], as well as in numerous diseases. It has
recently been reported that miRs are differentially modulated in
DMD, suggesting an important role of miRs in this disease [28–
32]. To address the potential mechanistic role of miRs in DMD
pathogenesis, we investigated whether miRs are involved in the
impaired expression of DAPC components during muscular
dystrophy. To this end, we used a well-established animal model
of DMD, mdx mice. These mice carry a mutation that results in the
absence of dystrophin and, subsequently, leads to a reduction of
other DAPC components. In mdx mice, muscle pathology starts at
two weeks of age and is characterized by a continuous cycle of
degeneration and regeneration of skeletal muscle cells that peaks
between three and four weeks of age. After this phase, the disease
becomes milder and is characterized by increasing muscular
fibrosis that lasts until the late phase of the animals life [38]. Based
on this progression pattern of the disease, we analyzed the RNA
and protein expression levels of some DAPC components at
different stages of the disease. Our results showed that in mdx
muscles, the protein level of b1-syntrophin was reduced compared
to that in muscles from 30-day- and five-month-old wt mice,
whereas, mRNA level of b1-syntrophin increased by 50%. The
elevated mRNA level excluded the possibility that a decrease in
gene expression was responsible for the protein loss. On the
contrary, there was no significant difference in protein and mRNA
Figure 5. miR-222 expression levels in wt and dystrophic
skeletal muscle tissues. A: MiR expression was evaluated by northern
blot analysis in the gastrocnemius muscle tissues from wt and mdx mice
of different ages; U6 levels were used as loading controls. A
representative blot from four experiments is shown. B: Northern blot
signals were quantified by densitometric analysis. The graph shows the
mean 6 SD from four independent experiments. For each experiment,
pooled muscle tissues were used (see Methods). The miR-222 levels in
dystrophic samples are expressed as fold change relative to those in
control samples. Statistical significance was determined as *P,0,05
versus wt (P=0,024 measured by the Mann-Whitney test).
doi:10.1371/journal.pone.0012098.g005
miR-222 in mdx
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and dystrophic muscles; however, all these proteins were clearly
absent in the cell membrane of dystrophic muscles, suggesting that
this absence is not due to a block in mRNA translation but more
likely due to impaired localization.
Based on these results, our studies focused on the potential post-
transcriptional mechanisms that might be involved in b1-
syntrophin regulation in dystrophic muscle tissues. In vivo
experiments confirmed that the absence of b1-syntrophin in
muscles from mdx mice was due to a block in translation. After
pEGFP-39-UTR-b1-synt was electroporated into the posterior
limb muscle of wt and mdx mice, histological analysis revealed that
GFP was clearly expressed in wt muscles, but only at a very low
level in mdx muscles, demonstrating a specific modulation of the
39-UTR. By analyzing this 39-UTR, we identified putative
consensus binding sites for three miRs: miR-24, miR-222 and
miR-339. All of these miRs were expressed in skeletal muscle
tissues of wt and dystrophic mice. MiR-222 level was higher in
dystrophic muscles compared to that in wt muscles, and the levels
increased with the progression of the disease. MiR-222 was also
the only miR specifically binding the 39-UTR of the b1-syntrophin
mRNA. MiR-222 expression was also detectable in primary
satellite cell cultures and was 50% higher in myogenic cells from
young mdx mice compared to that in wt cells.
Our data are in agreement with previous reports. In fact, miR-
222 has been found to be upregulated in 10 different myopathies:
a study by Eisenberg et al. [31] reported that a large number of
miRs were differentially expressed in various muscular pathologies
and, that, in particular, the expression of five miRs (miR-146b,
miR-221, miR-155, miR-214, miR-222) was altered in all the
Figure 6. Luciferase activity in the presence of miR-222. A: Luciferase activity in COS1 cells transfected with pGL3-39-UTR-b1-syntrophin was
assessed in the absence or presence of different concentrations of miR-222 and or antimiR (5610
28M). Luciferase activity was normalized to total
protein levels and calculated as the percentage of the values obtained from miR-transfected samples compared to those obtained from untreated
cells. Results are presented as the mean 6 SE from five independent experiments. Statistical significance was determined as *P,0,05 versus
untreated cells (P=0,0045 [2.5610
28M], P=0,0027 [5610
28M] measured by the Mann-Whitney test). B: Luciferase activity of COS1 cells was assessed
in cells transfected with pGL3-39UTR-b1-syntrophin or two vectors with mutations in the first (Mut1) or second (Mut2) putative binding site for miR-
222 in the absence or presence of 5610
28M of miR-222. Results are presented as the mean 6 SD from three independent experiments. *P,0,05
versus untreated cells (P=0,040 measured by the Mann-Whitney test).
doi:10.1371/journal.pone.0012098.g006
miR-222 in mdx
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expression in the adductor muscles from mdx mice and DMD
bioptic samples, and miR-222 was among the eleven dysregulated
miRs identified in that study. Together, these data indicated a
potential role of miRs in dystrophy and our data confirmed the
miR-222 upregulation in muscular dystrophy.
In addition, in agreement with a recent report by Cardinali et al.
[39], we also detected a reduction in miR-222 expression during
myogenic differentiation of C2C12 cells. These authors observed
that in quails, murine primary muscle cells, and myogenic rodent
cell lines, the miR-221/miR-222 cluster was highly expressed in
proliferating myoblasts but downregulated in differentiated
myotubes. The decreased expression of miR-222 during C2C12
differentiation could explain the corresponding two- to three-fold
increase in b1-syntrophin levels in differentiating versus prolifer-
ating C2C12 cells [40]. Cardinali et al. showed that p27 acts as a
Figure 7. miR-222 modulation of b1-syntrophin levels. Hep2 cells (A) and, muscle satellite cells from wt mice (B) or from mdx mice (C) were
transfected with miR-222 and/or antimiR-222. Total protein extracts were prepared and analyzed by western blot to assess b1-syntrophin levels. At
least three experiments were performed and representative experiments are shown. The graph values represent the mean 6 SD of the densitometric
analyses from independent experiments (n=3 for Hep2 cells and mdx satellite cells; n=4 for wt satellite cells). The data are presented as the
percentage of protein in treated cells compared to that in untreated cells, normalized to endogenous actin expression level. Statistical significance
was determined as *P,0,05 versus untreated cells, measured by the Mann-Withney test (Hep cells, P=0,019; wt satellite cells, P=0,036).
doi:10.1371/journal.pone.0012098.g007
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miR in the myogenic process. In our study, we showed, for the first
time, that the b1-syntrophin protein is a target of miR-222.
Furthermore, overexpression of miR-222 in proliferating C2C12
myogenic cells, induced a modulation of myogenic miRs
suggesting a potential novel regulatory role of miR-222 in the
differentiation process.
We demonstrated that miR-222 modulates the b1-syntrophin
protein in the cells of different tissues. In muscle cells and the
hepatic cell line Hep2, it was shown that endogenous b1-
syntrophin protein levels were reduced after transfection with
miR-222 and that the inhibitory effect of miR-222 was blocked in
the presence of anti-miR-222, which then restored b1-syntrophin
protein expression to normal. In satellite dystrophic cells
expressing high levels of miR-222, anti-miR-222 treatment slightly
increased b1-syntrophin protein levels. This experiment clearly
indicates that the impairment of b1-syntrophin protein expression
in dystrophic cells is due to the elevated levels of endogenous miR-
222, and that b1-syntrophin protein levels can be restored by anti-
miR treatment.
In addition to its structural role, b1-syntrophin may also
perform an important cell signaling role. In different tissues,
several partners have been identified to bind b1-syntrophin,
including the ATP binding cassette transporter A, the a1D
adrenergic receptor isoform, the voltage-gated sodium channel
Nav1.5 and, the potassium channel Kir2 [41–45]. Given its
scaffold b1-syntrophin may play an important role in muscle
diseases by regulating signaling complex localization. In particular,
loss of b1-syntrophin could impair the function of ionic channels at
specific sarcolemma regions, such as neuromuscular junctions.
Indeed, b1-syntrophin is mainly localized on the sarcolemma of
the type IIb-fast twitch muscle fibers, that are preferentially
affected in DMD [34], suggesting that the absence of b1-
syntrophin could worsen the disease. Thus, a fine regulation of
b1-syntrophin protein levels is necessary for it to exert proper
signaling and mechanical roles, allowing for the appropriate cell
function.
In conclusion, our results showed that in dystrophic muscle
increased miR-222 expression lead to the decrease in b1-
syntrophin expression by specifically binding to the 39-UTR of
b1-syntrophin. A specific antagonist of miR-222 allow rescued b1-
syntrophin protein expression in dystrophic satellite cells. These
data demonstrate, for the first time, that miRs are involved in the
regulation of the DAPC components in dystrophic muscles. The
involvement of miRs in the pathophysiology of muscle diseases
suggests that these molecules could serve as potential targets for a
complementary novel therapeutic approach, because silencing
miRs could enhance the expression of DAPC components.
Materials and Methods
Ethics statement
All procedures involving mice were completed in accordance
with the Italian National Institute of Health (protocol n. 118/99-
A) and the ethical guidelines for animal care of the European
Community Council (directive 86/609/ECC).
C57BL/6J mice and mdx mice were obtained from the Charles
River Laboratories Italia s.r.l. (Calco, Lecco, Italy) and were
housed in the animal facility of the Department of Histology and
Medical Embryology under a 12-h light-dark schedule at a
constant temperature and with food and water ad libitum. Animals
were sacrificed by carbon dioxide asphyxiation. To minimize
unnecessary suffering, before gene delivery into tibialis muscles,
the mice were anesthetized by an intra-peritoneal injection of a
solution of 80 to100 mg/kg ketamine (Intravet, Italy) +10 mg/kg
xylazine (Sigma-Aldrich, St. Louis, MO, USA).
After the animals were sacrified, skeletal muscle tissues were
collected and divided into three pieces: two were frozen in liquid
nitrogen for RNA and protein extractions, and one was frozen in
liquid nitrogen cooled isopentan, for immunological studies. All
samples were stored at 280uC.
Database analysis
We used the target prediction programs: the Miranda package
and targetscan, available at the following website location: http://
microrna.sanger.ac.uk; http://www.targetscan.org; http://www.
microrna.org.
RNA preparation and analysis
RNA was isolated from muscle tissue samples of wt and mdx
mice of different ages. Four different RNA samples were prepared,
each from tissue pools obtained by combining muscles from
multiple mice (n=6, 20-day-old, n=2, 30-day-old, n=2, five-
month-old wt mice; n=8, 20-day-old, n=4, 30-day-old, n=2,
five-month-old mdx mice). Total RNA was extracted using the
Trizol reagent (Invitrogen, Carlsbard, CA, USA) according to the
manufacturer’s instructions. RNA expression was determined by
northern blot analysis and/or qRT-PCR [46]. Northern blot was
performed using 30 mg of total RNA that was separated on a 15%
denaturing polyacrylamide gel and transferred from the gel to a
Hybond-N
+ membrane (Amersham Biosciences/GE Healthcare,
Piscataway, NJ). Blotted membranes were fixed by UV cross-
linking and heating at 80uC for 1 h, and processed for
hybridization. Hybridization was carried out overnight at 38uC
in a hybridization buffer containing 5X SSC [20X SSC: 3M
NaCl, 0.3 M NaCitrate], 20 mM Na2HPO4 pH 7.2, 7% SDS,
50% formamide, 50 mg/ml salmon sperm DNA and 10
6 cpm/ml
of radiolabed probe. The probes were oligonucleotides synthesized
on the basis of sequences complementary to the corresponding
miR (see Table 1) and labelled at the 59end with
32P-cATP.
Membranes were washed in 5X SSC and 0.2% SDS at 37uC and
2X SSC and 0.2% SDS at 37uC and then exposed to a Fuji
phosphoimager screen. Detection was performed using a phospho-
imager after an overnight exposure. The same filters were then
hybridized with a U6 probe to normalize the RNA levels for
quantitative analysis with a densitometer.
Quantitative real-time RT-PCR was performed using the
DyNAmo SYBR Green 2-step qRT-PCR kit (Finnzymes,
Kellaranta, Finland) or the TaqMan MicroRNA Assay kit
(Ambion/Applied Biosystem, Piscataway, NJ, USA) according to
the protocol for use in the Applied Biosystems 7500 Fast Real-
Time PCR System. For quantification analysis the comparative
threshold cycle (Ct) method was used. The Ct values of each gene
were normalized to the Ct value of GAPDH or Sno142 in the
same RNA sample. Gene expression levels were evaluated as fold
change using the equation 2
2ddCt.
The primers used are reported in Table 1.
Vector constructs
The 39-UTR of b1-syntrophin was synthesized by RT-PCR.
T h em R N As e q u e n c eo fb1-syntrophin was retrieved from
GenBank (U89997). Based on this sequence, oligonucleotide
couples flanking the 39-UTR were designed, synthesized and
used as primers for RT-PCR. The PCR product was cloned
into a PCR-TOPO vector (InVitrogen, Carlsbard, CA, USA),
sequenced and, subsequently, subcloned into a luciferase
reporter plasmid, pGL3basic (Promega, Madison, WI, USA)
f o rl u c i f e r a s ea s s a y .T h es a m e3 9-UTR DNA fragment was
miR-222 in mdx
PLoS ONE | www.plosone.org 9 August 2010 | Volume 5 | Issue 8 | e12098subcloned into pEGFP-C (Clontech, Takara Bio USA, CA,
USA) at the 39-end of the EGFP construct in which GFP
expression is driven by the CMV promoter. Mutations in the 39-
UTR of b1-syntrophin, were introduced using the Quick
Change site-directed mutagenesis kit (Stratagene, La Jolla, CA,
USA). Oligonucleotide primers for cloning and mutagenesis are
listed in Table 1.
Cell culture, transfection and luciferase assays
Transfection was performed using the Lipofectamine 2000
reagent (InVitrogen; Carlsbard, CA, USA) according to the
manufacturer’s protocol.
To assess luciferase activity, COS-1 cells (ATCC, CRL-1650)
were cultured in DMEM supplemented with 10% fetal calf serum.
One day prior to the transfection, the cells were plated onto 12-
well plates at a density of 80,000/well. The next day, the cells were
co-transfected with 1 mg of the pGL3 constructs, and appropriate
amounts of miR (Ambion/Applied Biosystem, Piscataway, NJ,
USA) and Lipofectamine 2000. The cells were cultured for 4 h in
DMEM without serum or antibiotics. Afterwards, the medium was
changed, and the cells were incubated in medium supplemented
with serum. After 24 h, the cells were collected and homogenized
in 70 ml of lysis buffer (Promega, Madison, WI, USA). The cell
lysates were centrifuged for 5 min at 12,000 g. Luciferase activity
was detected using the luciferase reporter assay system (Promega)
and measured by a luminometer. Protein concentration was
determined by the BCA assay (Pierce/Thermo Scientific, Rock-
ford, IL, USA).
For western blot analysis, the cells were plated at a density of
70,000/well and transfected either with or without 5610
28 M
miR-222 or antimiR-222 (Ambion/Applied Biosystem, Piscat-
away, NJ, USA). After an incubation of 4 h in medium without
serum or antibiotics, the cells were incubated for another 36 h in
medium supplemented with serum. At the end of the incubation
time, the cells were collected and homogenized in 70 mlo f
Laemmli buffer. The following cell lines were used: C2C12 (ATCC,
CRL-1772) and Hep2 (ATCC, CCL-23).
In another series of experiments, C2C12 cells were transfected
with miR-222 or antimiR-222 and the expression levels of miR-1,
miR-133, miR-206 were measured. One day prior the transfec-
tion, the cells were plated at a density of 10,000/cm
2. The next
day the cells were co-transfected with 5610
28 M miR or antimiR
(Ambion/Applied Biosystem, Piscataway, NJ, USA) and Lipofec-
tamine 2000. The cells were cultured for 4 h in DMEM without
serum or antibiotics. Afterwards, the medium was changed, and
the cells were incubated in medium supplemented with serum.
After 24 h, the cells were collected, and RNA was prepared using
the Trizol reagent as indicated above.
Primary cell cultures
Primary cell cultures were performed according to Matthew et
al. [47]. Briefly, dissected muscles from five to six one-week-old
animals (n=20 wt and 24 mdx mice in total) were minced by a
razor blade and then digested by collagenase/dispase. The
resulting cellular suspension was plated for a few hours to remove
contaminating fibroblasts, and the unattached muscle cells were
collected and plated on collagene-coated dishes in DMEM
(Gibco/InVitrogen, Carlsbard, CA, USA) supplemented with
10% serum. The cultured cells were later processed for
transfection experiments and western blot analysis.
Protein analyses
Frozen muscle tissue samples from wt and mdx mice were
homogenized in lysis buffer (2% SDS, 5 mM EDTA) supplement-
ed with proteinase inhibitors, boiled for 5 minutes and centrifuged
at 12,000 g for 10 min [48]. Protein concentration was deter-
mined by the BCA assay (Pierce/Thermo Scientific, Rockford, IL,
USA). For each preparation multiple muscle tissues were pooled
(n=2, 30-day-old and n=1 wt 5-month-old wt mice; n=3, 30-
day-old and n=1, 5 month-old mdx mice.)
Protein aliquots ranging from 30–40 mg were separated by
electrophoresis on a 10% SDS-acrylamide gel and transferred
onto a nitrocellulose membrane. The blotted membranes were
blocked in TBS-T (20 mM Tris-HCl pH 7.5, 137 mM NaCl, and
Table 1. primers used in RNA analysis.
Dag (cDNA) 59-GAGGACCAGGCCACCTTTATTAAG-39 (forward primer)
59-TTAAGGGGGAACATACGGAG-39 (reverse primer)
a-synt (cDNA) 59-ATGGCGTCAGGCAGGCGCGC-39 (forward primer)
59-GCCTCCGTCTGGTCTGCTGC-39 (reverse primer)
b1- synt (cDNA) 59-CAGTCCCCTTATG AGAAGCTC-39 (forward primer)
59-TCAGGCCACGCCCAGTC-39 (reverse primer)
GAPDH 59-ATCACTGCCACCCAGAAGACT-39 (forward primer)
59-CATGCCAGTGAGCTTCCCGTT-39 (reverse primer)
b1-synt (39UTR) 59-ACAGAGGGCGACTTGCCTTTGG-39 (forward primer)
59-GGAGACAGCATCCAGGGGTGTGG-39 (reverse primer)
b1-synt (39UTR mut1) 59-CAGGACTGTGACATCAGGCAGTGCAACATGCACAGCCAG
GTTCAGGTT-39 (forward primer)
59-AACCTGAACCTGGCTGTGCATGTTGCACTGCCTGATGTCA
CAGTCCTG-39 (reverse primer)
b1-synt (39UTR mut2) 59-AGCCAGGTTCAGGTTTAAGGAACATCCCAGCCTCCTCTAT-39 (forward primer)
59-ATAGAGGAGGCTGGGATGTTCCTTAAACCTGAACCTGGCT-39 (reverse primer)
miR-222 59-GAGACCCAGTAGCCAGATGTAGCT-39
U6 59-TTGCGTGTCATCCTTGCGCAGG-39
EGFP 59- CAT GGT CCT GCT GGA GTT CGT G -39 (forward primer)
59- CAG GGG GAG GTG TGG GAG GT -39 (reverse primer)
doi:10.1371/journal.pone.0012098.t001
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room temperature, and then incubated with specific antibodies
diluted in the same buffer, overnight at 4uC. The membranes were
washed several times with TBS-T and then probed with secondary
antibodies coupled to horseradish peroxidase. The immunoreac-
tive bands were visualized by chemiluminescence (ECL or ECL
plus kit, Amersham Biosciences/GE Healthcare, Piscataway, NJ).
Densitometric analysis was performed using the AIDA 2.2 image
software. The optical density (OD) of each signal was normalized
to a-actin. The following antibodies were used: mouse anti-a
syntrophin (Sigma-Aldrich, St. Louis, MO, USA), goat anti b1-
syntrophin (Santa Cruz Biotechnology; Santa Cruz, CA, USA),
rabbit anti-b1-syntrophin (antibody SYN37, generously provided
by Dr. Stanley Froehner, University of Washington, Seattle WA),
mouse anti a-b syntrophins (Affinity Bioreagents, Golden, CO,
USA), mouse anti-a and anti-b-dystroglycan (SantaCruz Biotech-
nology; Santa Cruz, CA, USA), and mouse anti-actin and anti-
tubulin (Chemicon/Millipore, Billerica, MA, USA).
Immunoprecipitation analyses were performed following a
standard protocol as previously described [49]. Muscle tissue
fragments from young and adult wt and mdx mice were lysed in
RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM
EDTA, 1% NP-40, 0.25% deoxycholate, and 0.1% SDS) and
aliquots containing 1 mg of protein extracts were incubated
overnight at 4uC with an antibody anti a-b-syntrophins (Affinity
Bioreagents, Golden, CO, USA). The protein-antibody complex
was recovered by incubation with protein G-sepharose, separat-
e do nS D S - P A G Ea n dp r o b e dw i t ha na n t i - b1-syntrophin
antibody.
To determine the localization of different proteins, immunoflu-
orescence analysis, was performed as documented [50]. 7 mm
sections were prepared from frozen muscles, permeabilized with
0.1% Triton-X-100, blocked with 5% BSA-TBS-T and incubated
with primary antibodies. The specific proteins were visualized
using secondary antibodies coupled to a fluorescent marker
(fluorescein isothiocyanate, FITC or Texas red; Pierce, Thermo-
scientific, Rockford, Il, USA). Immunostained samples were
counterstained with DAPI (49,69-diamidino-2-phenylindole dihy-
drochloride: Molecular Probes, Eugene, OR) and examined by a
Zeiss Axioskop2 plus microscope. Images were obtained with a
Zeiss AxioCam HRc using the Axiovision software.
The following antibodies were used: a-dystroglycan clone
VIA4-1 (Millipore, Billerica, MA, USA), b-dystroglycan clone
43DAG1/8D5 (Monosan, Uden, NL), a-syntrophin RA16-1
(Sigma-Aldrich, St. Louis, MO, USA), b1-syntrophin clone C20
(SantaCruz Biotechnology, Santa Cruz, CA, USA).
For this analysis, a total of n=3 wt mice and n=3 mdx adult
mice were used.
Gene delivery into tibialis muscles
In vivo experiments were performed on 30-days-old wt (n=3)
and mdx mice (n=5) or 5-month-old mdx mice (n=2) [51]. Tibialis
anterior muscles were exposed using a short incision and 20 mlo fa
solution of 5% mannitol containing 20 mg of DNA (pEGPF2C1
or pEGFP-39UTR-b1-synt) was injected using a Hamilton syringe
in the central part of the muscle. One leg received the empty
vector pEGPF-C1, the other the pEGFP-39UTR-b1-synt con-
struct. Afterwards, the muscle was separated from tibia, and a pair
of spatula-like electrodes (0.5 cm wide, 2 cm long) were placed at
each side of the muscle close to the injection site (anode was
positioned under the muscle in transverse direction relative to the
fibers, and cathode was placed on the muscle in longitudinal
direction) and electric pulses were delivered. Six electric pulses
with the fixed pulse duration of 50 msec/pulse, were delivered at
an interval of 200 ms using an electric pulse generator. The ratio
of applied voltage to electrode distance was 5V/mm (muscle
thickness). Mice were sacrificed 24 h after the electroporation and
muscles were removed, frozen in liquid nitrogen-cooled isopentan,
and then processed for morphological analysis.
Several 7-mm thick cryostat sections, upstream and downstream
of the injection site were prepared, GFP expression was examined
using a Zeiss Axioskop2 plus fluorescence microscope (Carl Zeiss,
Oberkochen, Germany). As a control for gene delivery, PCR
and RT-PCR analyses were performed on genomic and RNA
samples, respectively. Oligonucleotide primers for GFP are listed
in Table 1.
Statistical analysis
Data are presented as mean 6 standard deviation (SD) or
standard error (SE). Statistical significance between groups was
determined using the GraphPad Prism software. The non
parametric-Mann-Whitney test was done for the analysis of
RNA expression, protein expression and luciferase activity when
sample groups were small. The unpaired t-test was performed to
assess the significativity of gene delivery experiments. P values of
less than 0.05 were considered statistically significant.
Supporting Information
Figure S1 Dystroglycan protein expression. A: Total protein
extracts were obtained from the gastrocnemius muscle tissues of wt
and mdx mice of different ages (30 d, 30-day-old mice; 5 m: five-
month-old mice) and were resolved by SDS-PAGE and transferred
to nitrocellulose membrane. The membrane was probed with a
and b-dystroglycan antibodies. Representative western blots are
shown. The graph values represent the mean 6 SD of the
densitometric analyses from three independent experiments; the
data are presented as the percentage of protein in mdx mice
compared to that in wt mice, normalized to endogenous tubulin
expression level. B: The gastrocnemius muscle sections from wt
and mdx adult mice were probed with a and b2dag antibodies
and visualized using secondary antibody coupled to a fluorescent
marker, Texas red or FITC.
Found at: doi:10.1371/journal.pone.0012098.s001 (7.35 MB
TIF)
Figure S2 b1-syntrophin protein expression. A representative
experiment of immunoprecipitation is shown. Whole homogenates
obtained by RIPA buffer extraction were immunoprecipitated
with an antibody against syntrophins. The immunomplexes were
separated on an SDS-PAGE and probed with a b1-syntrophin
specific antibody. The experiment was performed twice with
similar results.
Found at: doi:10.1371/journal.pone.0012098.s002 (0.28 MB
TIF)
Figure S3 miR-222 modulation of myogenic miRs expression.
RNA levels of miR-206, miR-1, and miR-133 in C2C12 cells
transfected with miR-222 (5610
28M) or anti-miR-222
(5610
28M) were assessed by qRT-PCR; relative gene expression
was calculated by the comparative Ct method (2
2ddCt). The Ct
values of each miR were normalized to the Ct value of sno142 in
the same RNA samples. RNA levels in cells treated with miR-222
or anti-miR-222, are expressed as fold change compared to those
in the untreated cells. A representative of the two performed
experiments is shown. All values represent the mean 6+ SD from
triplicate samples.
Found at: doi:10.1371/journal.pone.0012098.s003 (2.02 MB
TIF)
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